- ArQule (NASDAQ:ARQL) upgraded to Buy with a $5 (285% upside) price target by Needham.
- BioMarin Pharmaceutical (NASDAQ:BMRN) upgraded to Outperform with a $110 (26% upside) price target by Wedbush.
- Esperion Therapeutics (NASDAQ:ESPR) upgraded to Strong Buy with an $81 (42% upside) price target by Needham.
- GW Pharmaceuticals (NASDAQ:GWPH) upgraded to Buy with a $174 (40% upside) price target by Goldman Sachs (NYSE:GS).
- Community Health Systems (NYSE:CYH) downgraded to Underweight by JPMorgan (NYSE:JPM) with no price target citing no benefit from tax reform, high degree balance sheet leverage and structural changes in the hospital sector.
- Spark Therapeutics (NASDAQ:ONCE) downgraded to Neutral with a $58 (26% upside) price target by Goldman Sachs.
- Tenet Healthcare (NYSE:THC) downgraded to Underweight by JPMorgan with a $15 (flat) price target for the same reasons cited for CYH.
- Now read: BioMarin, Spark, And Insertional Oncogenesis
Original article